Work

Impact of the COVID-19 pandemic on maternal-fetal toxoplasmosis screening and incidence: a retrospective study

Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction: toxoplasmosis, although often benign, poses significant risks during pregnancy due to the possibility of congenital toxoplasmosis (CT). Maternal-fetal screening relies on early toxoplasma serology and monthly monitoring of seronegative women. Since 2020, the COVID-19 pandemic has disrupted routine screening programs. This study aimed to describe serological follow-up at our university hospital before and during the pandemic and assess its impact on CT incidence. Methods: we conducted a retrospective study including all maternal toxoplasma serologies sent to the Parasitology Laboratory of Farhat Hached University Hospital, Sousse, from January 2016 to December 2021. Screening quality was assessed by the number of serologies per pregnancy and gestational age at the first test. Results: a total of 33,786 maternal serologies were processed. Annual requests remained stable (~7,000) until 2019 but fell below 4,000 after the pandemic onset. From 2016 - 2019, 15% of women had ≥3 serologies, with half having the first test before 10 weeks of gestation. Post-pandemic, only 11% had >2 serologies, and 39% were screened before 10 weeks. First-time postpartum serologies doubled from 2% to 4.8%. Ninety-four maternal infections were identified, with an annual peak of 8.7% in 2020. Seven CT cases were confirmed, four of which occurred in 2020 - 2021; one was diagnosed antenatally. Conclusion: adherence to recommended maternal-fetal toxoplasmosis screening declined significantly during the COVID-19 pandemic. These findings highlight the urgent need to raise awareness among healthcare providers and strengthen preventive measures for seronegative pregnant women.
Language: English
Subfield: Parasitology
Open Access status: gold
Estimated APC paid: $180
OpenAlex ID: W7225827520
FWCI:
Cites: 19
Cited by:
Related to: 10